- $68.12m
- $43.65m
- $0.92m
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million
Israel's Rafael could begin privatization as early as end of 2026, chairman says
Rafael Holdings' Q1 net loss widens as expenses rise after Cyclo acquisition
Brief: Rafael Holdings Q1 Net Income USD -9.797 Million
Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses
Brief: Rafael Holdings Q4 Net Income USD -12.054 Million
Brief: Rafael Holdings Announces Final Results And Closing Of Rights Offering
Brief: Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
Brief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Brief: SEC Issued An Order Instituting Administrative Proceedings Against Howard Jonas
Cyclo Therapeutics falls after merger agreement with Rafael Holdings
Brief: Rafael Holdings And Cyclo Therapeutics Enter Into A Definitive Merger Agreement
Cyclo Therapeutics falls after merger agreement with Rafael Holdings
Brief: Cyclo Therapeutics Achieves Landmark Milestone With Completion Of Enrollment Of Last Patient In Phase 3 Pivotal Transportnpc™ Trial Of Niemann-Pick Type C1
Brief: Cornerstone Pharmaceuticals Consummated Restructuring Of Its Outstanding Debt And Equity Interests
Brief: Rafael Holdings Reports Q3 Loss Per Share Of $0.06